Aerska, a biotech focusing on RNA interference, raised $21 million to develop antibody-oligo conjugates for delivering RNAi drugs across the blood-brain barrier targeting neurological diseases like genetic Alzheimer's and Parkinson's. Concurrently, insights into RNA pseudouridylation and its role in antiviral immunity and cancer immunotherapy sensitivity have been elucidated. These advances underscore expanding RNA-based therapeutic modalities targeting challenging indications with potential broad impact.